| Name | Title | Contact Details |
|---|
Fatima Group is one of the largest business conglomerates in Pakistan operating in diversified sectors like Fertilizers, Textiles, Sugar, Energy, Packaging, Mining & Trading of commodities. Established in 1936 with trading of commodities and gradually entered into the manufacturing of various products. The Group has a success story spread over seven decades, expanding its horizon from trading to manufacturing. With an annual turnover of over 80 billion PKR and more than 6,300 employees, Fatima Group plays an important role in the economic development of the country.
Our dedicated attorneys with impressive trial experience and impeccable reputations represent clients nationwide and can help change your life by legalizing your status so you can remain here with your family, for good. Our mission is to bring compassion back to law by protecting client rights, representing and fighting for what our clients deserve. Far too often we see genuine, good people silenced because they dont have the resources they need to see their case through. Nothing can feel more intimidating than sorting through paperwork, keeping track timelines, and navigating the complex immigration system. Our attorneys advocate ruthlessly for your rights with compassionate representation. We anticipate the needs of our clients and are well-versed in proactive planning if you or a loved one are in need immigration support. As our client, you will always be our top priority. That is our promise.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.